Key result
POLARx FIT is associated with a ~3 °C higher RIPV nadir temperature vs standard POLARx.
Why the study?
The study aimed to compare the benefits and safety of the novel POLARx FIT system to the existing POLARx system for pulmonary vein isolation in patients with atrial fibrillation.
Does the novel expandable POLARx FIT cryoballoon system improve procedural efficacy and safety compared to the conventional 28-mm POLARx system for pulmonary vein isolation in patients with atrial fibrillation?
Cohort (n=270)
No
Does the novel expandable POLARx FIT cryoballoon system improve procedural efficacy and safety compared to the conventional 28-mm POLARx system for pulmonary vein isolation in patients with atrial fibrillation?
The expandable POLARx FIT cryoballoon achieves wider ablation lesions and eliminates residual carina potentials compared to standard systems, but frequently requires intraprocedural downsizing for adequate pulmonary vein occlusion.
Higher nadir temperatures with POLARx FIT in right inferior veins warrant monitoring; leaves open effects on lesion durability and outcomes.
Background: The POLARx FIT system (Boston Scientific, MA, USA) is a novel cryoballoon (CB) ablation technology in which the balloon diameter can be expanded from 28 to 31 mm. The aim of this study was to compare the benefits and safety of the new POLARx FIT system to those of the existing POLARx system currently in use for pulmonary vein (PV) isolation (PVI) in patients with atrial fibrillation. Methods: The first 70 consecutive patients who underwent CB-based PVI with the POLARx FIT system were retrospectively compared with 200 consecutive patients treated with the POLARx system at Sakakibara Heart Institute from October 2021 to May 2023. Results: The POLARx FIT system yielded a higher mean ± standard deviation nadir temperature in the right inferior PV (-59.2 ± 5.29 °C vs. - 62.0 ± 5.08 °C, p = 0.006), but this required a balloon size reduction to 28 mm in 30 % of cases. No significant differences were detected in the time to isolation and thaw time of any PV between the two groups. After the CB-based PVI procedure, no residual PV carina potentials were observed with the POLARx FIT system, whereas 4/20 were with the POLARx system (p = 0.04). Conclusions: The POLARx FIT system had comparable effectiveness and safety to the basic POLARx system. This technology may improve the ablation area, including the PV carina. However, the 31-mm balloon alone was not sufficient to isolate certain PVs.
No takes yet. Share an insight, caveat, or question.
Fukunaga et al. (2023) conducted a cohort in Paroxysmal and persistent atrial fibrillation (n=270). POLARx FIT cryoballoon system vs. POLARx system was evaluated on Residual pulmonary vein carina potentials (p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: